DOCSLIB.ORG

Comparative Effectiveness of Sodium- Glucose Co-Transporter 2 Inhibitors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Open Access Protocol BMJ Open: first published as 10.1136/bmjopen-2015-010252 on 29 January 2016. Downloaded from Comparative effectiveness of sodium- glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysis Min Chen,1 Chun-Guang Xie,1 Hong Gao,1 Hui Zheng,2 Qin Chen,3 Jian-Qiao Fang3 To cite: Chen M, Xie C-G, ABSTRACT et al Strengths and limitations of this study Gao H, . Comparative Introduction: As a new class of glucose-lowering effectiveness of sodium- drugs, sodium-glucose co-transporter 2 (SGLT2) ▪ glucose co-transporter 2 We will include recently published studies that inhibitors are effective for controlling hyperglycaemia, inhibitors for controlling assessed incidence of cardiovascular disease, hyperglycaemia in patients however, the relative effectiveness and safety of 6 ketoacidosis and cancer caused by SGLT2 inhibi- with type 2 diabetes: protocol recently available SGLT2 inhibitors have rarely been tors, which will add knowledge to the safety of for a systematic review and studied. Therefore, we aim to perform pairwise SGLT2 inhibitors. network meta-analysis. BMJ comparisons of the 6 SGLT2 inhibitors. ▪ The result of this meta-analysis will help patients Open 2016;6:e010252. Methods and analysis: A systematic review and with type 2 diabetes, clinicians and policymakers doi:10.1136/bmjopen-2015- network meta-analysis will be conducted. Clinical in selecting a SGLT2 inhibitor for controlling 010252 studies that examine effectiveness and safety of either hyperglycaemia. canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, ▪ A possible limitation is that we may not have ▸ Prepublication history for tofogliflozin or luseogliflozin will be included. These enough data to perform pairwise comparisons this paper is available online. studies will be systematically retrieved in MEDLINE, between the SGLT2 inhibitors, since these inhibi- http://bmjopen.bmj.com/ To view these files please EMBASE and the Cochrane Library, from inception to tors will be compared in four situations: mono- visit the journal online November 2015. Two reviewers will independently therapy, dual therapy, triple or quadruple therapy (http://dx.doi.org/10.1136/ screen for eligible studies and then extract data bmjopen-2015-010252). and in combination with insulin. from the studies as well as assess risk of bias. Discrepancies in screening and data extraction will be arbitrated by a third reviewer. A traditional meta- INTRODUCTION MC and C-GX contributed analysis will be performed to combine the effect sizes Hyperglycaemia is a major manifestation of equally to this work. calculated from head-to-head comparisons with a diabetes mellitus. The most important bio- on September 25, 2021 by guest. Protected copyright. random effect model. The effect sizes computed from Received 13 October 2015 indirect comparisons will be further combined in a marker of hyperglycaemia is glycated haemo- Revised 7 December 2015 network meta-analysis. Heterogeneity will be tested globin (HbA1c). Including HbA1c to the Accepted 29 December 2015 with the Cochrane’s Q statistic, and publication bias diagnostic criteria accounts for a 75% will be assessed using a funnel plot and the Egger’s increase of individuals with diabetes mellitus test. across all age-groups.1 Patients with elevated Ethics and dissemination: Relative effectiveness HbA1c level are at high risk for developing and harms of the 6 SGLT2 inhibitors will be diabetic retinopathy and cardiovascular – demonstrated through this systematic review and disease.2 4 Lowering HbA1c to <7.0% signifi- network meta-analysis. The result of the review will cantly reduces the risk of microvascular com- – be disseminated through a peer-review journal and plications in patients with type 2 diabetes.5 7 conference presentations. Patients, clinicians and Given that type 2 diabetes is, globally, a For numbered affiliations see policymakers will benefit from this review in selecting end of article. major public health problem (affecting 347 a SGLT2 inhibitor for glucose control in patients 8 with type 2 diabetes. million individuals in the year 2008), strin- Correspondence to Trial registration number: PROSPERO gent control for hyperglycaemia is needed. Professor Jian-Qiao Fang; CRD42015025981. As a new class of drugs, sodium-glucose [email protected] co-transporter 2 (SGLT2) inhibitors are Chen M, et al. BMJ Open 2016;6:e010252. doi:10.1136/bmjopen-2015-010252 1 Open Access BMJ Open: first published as 10.1136/bmjopen-2015-010252 on 29 January 2016. Downloaded from recommended in a report on hyperglycaemia manage- canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, ment released by the American Diabetes Association tofogliflozin and luseogliflozin. After evaluating the eligi- (ADA) and the European Association for the Study of bility of potential studies, we will collect data from them Diabetes (EASD).9 SGLT2 inhibitors activate at the prox- and assess risk of bias. In the network meta-analysis, we imal nephron to decrease glucose absorption, so they are will combine both—direct and indirect comparisons— independent of insulin and therefore can be used in any using a statistical package of ‘netmeta’ which has been stage of type 2 diabetes. Several systematic reviews have designed for pairwise comparisons in a frequentist shown that SGLT2 inhibitors are effective for controlling framework. This study has been registered at – HbA1c.10 17 In these reviews, when different doses of a PROSPERO (http://www.crd.york.ac.uk/PROSPERO) SGLT2 inhibitor are tested in a trial, only the highest with registration number CRD42015025981. dose of this SGLT2 is chosen to include for meta-analysis. In addition, some reviews summarise canagliflozin, dapa- gliflozin and empagliflozin in the same category, and DATA SOURCE assess them as one treatment, ignoring heterogeneity in We will search for studies that examined effectiveness 13 14 18 their treatment effects. Rosenstock et al found that and adverse events of the 6 SGLT 2 inhibitors in the fol- 50 mg canagliflozin worked better than 200 mg canagli- lowing electronic databases: MEDLINE (via Ovid), flozin in lowering HbA1c. A similar finding of EMBASE ( http://www.embase.com) and the Cochrane dose-ranging effect of dapagliflozin was discovered in a library, from inception to November 2015. Table 1 shows 12 systematic review. Therefore, we hypothesise that the a search strategy developed with comprehensive use of treatment effects of canagliflozin, dapagliflozin and medical subject headings and keywords. Besides the empagliflozin are different, especially when administered electronic search, we will also perform a manual search in different doses. Recently, three new SGLT2 inhibiting for conference abstracts or e-posters in the areas of drugs (ipragliflozin, tofogliflozin and luseogliflozin) were introduced to clinical practice and tested by rando- Table 1 Search strategy for MEDLINE (via OVID) 19–21 mised controlled trials, but they were not included No. Search terms in previous systematic reviews. A systematic review proto- col was recently published to evaluate the efficacy of 1 randomized controlled trial.pt. SGLT2 inhibitors by comparing them to placebo.22 2 controlled clinical trial.pt. 3 randomized.ab. However, this systematic review did not assess the efficacy fl fl fl 4 randomised.ab. of ipragli ozin, tofogli ozin and luseogli ozin, nor did it 5 placebo.ab. assess their relative effectiveness. Additionally, adverse 6 randomly.ab. events of the 6 SGLT2 inhibitors have not been fully eval- 7 trial.ab. uated in previous reviews, especially for events such as 8 groups.ab. http://bmjopen.bmj.com/ cardiovascular diseases, ketoacidosis and cancer. 9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 Methods of network meta-analysis (NMA) have been 10 exp hyperglycemia/ developed as alternative treatment options for disease con- 11 exp Diabetes Mellitus, Type 2 / ditions, however, increased and comparative effectiveness 12 hyperglycemia. ti, ab. research is needed. NMA can be carried out using frequen- 13 Type 2 diabetes. ti, ab. tist or Bayesian statistics.23 Lumley developed a package, 14 10 or 11 or 12 or 13 15 sodium glucose co-transporter. ti, ab. ‘NLME’, for conducting NMA in a frequentist framework,24 16 SGLT2. ti, ab. on September 25, 2021 by guest. Protected copyright. with a major advantage of addressing inconsistency in the 17 Canagliflozin. sh, ti, ab. network to assess the uncertainty in treatment estimates. 18 Dapagliflozin. sh,ti, ab. However, the ‘NLME’ package could not handle a trial with 19 Empagliflozin. sh, ti, ab. threeormorearms.AsthetechniquesofNMAdevelop, 20 ipragliflozin. sh, ti, ab. Rucker has proposed a new NMA statistical solution to deal 21 tofogliflozin. sh, ti, ab. with trials that have three or more arms,25 with the advan- 22 luseogliflozin. sh, ti, ab. tage of addressing inconsistency within and between trials as 23 A10BX11. sh, ti, ab. well as adjusting treatment estimates in trials with multiple 24 A10BX09. sh, ti, ab. arms. Therefore, we aim to test the relative effectiveness and 25 A10BX12. sh, ti, ab. safety of canagliflozin, dapagliflozin, empagliflozin, ipragli- 26 ASP1941. sh, ti, ab. 27 CSG452. sh, ti, ab. flozin, tofogliflozin and luseogliflozin, using a systematic 28 TS-071. sh, ti, ab. review and NMA in a frequentist framework. 29 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 30 9 and 14 and 29 METHODS SGLT2, sodium-glucose co-transporter 2 inhibitor. A10BX11, A systematic review and network meta-analysis will be A10BX09, A10BX12, ASP1941, CSG452 and TS-071 are the performed. In the systematic review, we will retrieve clin- codenames for canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, tofogliflozin and luseogliflozin, respectively. ical studies that tested the effectiveness and safety of 2 Chen M, et al. BMJ Open 2016;6:e010252. doi:10.1136/bmjopen-2015-010252 Open Access BMJ Open: first published as 10.1136/bmjopen-2015-010252 on 29 January 2016. Downloaded from diabetes, in the ADA, EASD, Canadian Diabetes monotherapy, dual therapy, triple or quadruple therapy Association (CDA) and International Diabetes and in combination with insulin.
Recommended publications
  • View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0

    View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0

    Katakami et al. Cardiovasc Diabetol (2020) 19:110 https://doi.org/10.1186/s12933-020-01079-4 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Tofoglifozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study Naoto Katakami1,2* , Tomoya Mita3, Hidenori Yoshii4, Toshihiko Shiraiwa5, Tetsuyuki Yasuda6, Yosuke Okada7, Keiichi Torimoto7, Yutaka Umayahara8, Hideaki Kaneto9, Takeshi Osonoi10, Tsunehiko Yamamoto11, Nobuichi Kuribayashi12, Kazuhisa Maeda13, Hiroki Yokoyama14, Keisuke Kosugi15, Kentaro Ohtoshi16, Isao Hayashi17, Satoru Sumitani18, Mamiko Tsugawa19, Kayoko Ryomoto20, Hideki Taki21, Tadashi Nakamura22, Satoshi Kawashima23, Yasunori Sato24, Hirotaka Watada3 and Iichiro Shimomura1 on behalf of the UTOPIA study investigators Abstract Background: This study aimed to investigate the preventive efects of tofoglifozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT). Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofoglifozin treatment group (n 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n 171). Primary outcomes were changes= in mean and maximum common carotid IMT measured by echography during= a 104-week treatment period. Results: In a mixed-efects model for repeated measures, the mean IMT of the common carotid artery (mean- IMT-CCA), along with the right and left maximum IMT of the CCA (max-IMT-CCA), signifcantly declined in both the tofoglifozin ( 0.132 mm, SE 0.007; 0.163 mm, SE 0.013; 0.170 mm, SE 0.020, respectively) and the control group ( 0.140 mm,− SE 0.006; 0.190 mm,− SE 0.012; 0.190 mm,− SE 0.020, respectively).
  • Supplementary Material

    Supplementary Material

    Supplementary material Table S1. Search strategy performed on the following databases: PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL). 1. Randomi*ed study OR random allocation OR Randomi*ed controlled trial OR Random* Control* trial OR RCT Epidemiological study 2. sodium glucose cotransporter 2 OR sodium glucose cotransporter 2 inhibitor* OR sglt2 inhibitor* OR empagliflozin OR dapagliflozin OR canagliflozin OR ipragliflozin OR tofogliflozin OR ertugliflozin OR sotagliflozin OR sergliflozin OR remogliflozin 3. 1 AND 2 1 Table S2. Safety outcomes of empagliflozin and linagliptin combination therapy compared with empagliflozin or linagliptin monotherapy in treatment naïve type 2 diabetes patients Safety outcome Comparator 1 Comparator 2 I2 RR [95% CI] Number of events Number of events / / total subjects total subjects i. Empagliflozin + linagliptin vs empagliflozin monotherapy Empagliflozin + Empagliflozin linagliptin monotherapy ≥ 1 AE(s) 202/272 203/270 77% 0.99 [0.81, 1.21] ≥ 1 drug-related 37/272 38/270 0% 0.97 [0.64, 1.47] AE(s) ≥ 1 serious AE(s) 13/272 19/270 0% 0.68 [0.34, 1.35] Hypoglycaemia* 0/272 5/270 0% 0.18 [0.02, 1.56] UTI 32/272 25/270 29% 1.28 [0.70, 2.35] Events suggestive 12/272 13/270 9% 0.92 [0.40, 2.09] of genital infection i. Empagliflozin + linagliptin vs linagliptin monotherapy Empagliflozin + Linagliptin linagliptin monotherapy ≥ 1 AE(s) 202/272 97/135 0% 1.03 [0.91, 1.17] ≥ 1 drug-related 37/272 17/135 0% 1.08 [0.63, 1.84] AE(s) ≥ 1 serious AE(s) 13/272 2/135 0% 3.22 [0.74, 14.07] Hypoglycaemia* 0/272 1/135 NA 0.17 [0.01, 4.07] UTI 32/272 12/135 0% 1.32 [0.70, 2.49] Events suggestive 12/272 4/135 0% 1.45 [0.47, 4.47] of genital infection RR, relative risk; AE, adverse event; UTI, urinary tract infection.
  • Summary of Investigation Results Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors

    Summary of Investigation Results Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors

    Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Summary of investigation results Sodium-glucose co-transporter 2 (SGLT2) inhibitors September 15, 2015 Non-proprietary name a. Canagliflozin hydrate b. Dapagliflozin propylene glycolate hydrate c. Empagliflozin d. Ipragliflozin L-proline e. Luseogliflozin hydrate f. Tofogliflozin hydrate Brand name (Marketing authorization holder) a. Canaglu Tablets 100 mg (Mitsubishi Tanabe Pharma Corporation) b. Forxiga Tablets 5 mg and 10 mg (AstraZeneca K.K.) c. Jardiance Tablets 10 mg and 25 mg (Nippon Boehringer Ingelheim Co., Ltd.) d. Suglat Tablets 25 mg and 50 mg (Astellas Pharma Inc.) e. Lusefi Tablets 2.5 mg and 5 mg (Taisho Pharmaceutical Co., Ltd.) f. Apleway Tablets 20 mg (Sanofi K.K.) and Deberza Tablets 20 mg (Kowa Company, Ltd.) Indications Type 2 diabetes mellitus Summary of revision 1. Precautions regarding ketoacidosis should be added in the Important Precautions section for the above products from a to f. 2. “Ketoacidosis” should be newly added in the Clinically significant adverse reaction section for the above products from a to f. 3. “Sepsis” should be added to the “Pyelonephritis” subsection in the Important Precautions section for the above products from a to f. Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: [email protected] Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users.
  • Glucose Cotransporter 2 Inhibitor, Attenuates Body Weight Gain and Fat Accumulation in Diabetic and Obese Animal Models

    Glucose Cotransporter 2 Inhibitor, Attenuates Body Weight Gain and Fat Accumulation in Diabetic and Obese Animal Models

    OPEN Citation: Nutrition & Diabetes (2014) 4, e125; doi:10.1038/nutd.2014.20 & 2014 Macmillan Publishers Limited All rights reserved 2044-4052/14 www.nature.com/nutd ORIGINAL ARTICLE Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models M Suzuki1, M Takeda1, A Kito1, M Fukazawa1, T Yata2, M Yamamoto1, T Nagata1, T Fukuzawa1, M Yamane1, K Honda1, Y Suzuki1 and Y Kawabe1 OBJECTIVE: Tofogliflozin, a highly selective inhibitor of sodium/glucose cotransporter 2 (SGLT2), induces urinary glucose excretion (UGE), improves hyperglycemia and reduces body weight in patients with Type 2 diabetes (T2D). The mechanisms of tofogliflozin on body weight reduction were investigated in detail with obese and diabetic animal models. METHODS: Diet-induced obese (DIO) rats and KKAy mice (a mouse model of diabetes with obesity) were fed diets containing tofogliflozin. Body weight, body composition, biochemical parameters and metabolic parameters were evaluated. RESULTS: In DIO rats tofogliflozin was administered for 9 weeks, UGE was induced and body weight gain was attenuated. Body fat mass decreased without significant change in bone mass or lean body mass. Food consumption (FC) increased without change in energy expenditure, and deduced total calorie balance (deduced total calorie balance ¼ FC À UGE À energy expenditure) decreased. Respiratory quotient (RQ) and plasma triglyceride (TG) level decreased, and plasma total ketone body (TKB) level increased. Moreover, plasma leptin level, adipocyte cell size and proportion of CD68-positive cells in mesenteric adipose tissue decreased. In KKAy mice, tofogliflozin was administered for 3 or 5 weeks, plasma glucose level and body weight gain decreased together with a reduction in liver weight and TG content without a reduction in body water content.
  • Effect of Luseogliflozin on Bone Microarchitecture in Elderly Patients with Type 2 Diabetes

    Effect of Luseogliflozin on Bone Microarchitecture in Elderly Patients with Type 2 Diabetes

    Effect of luseogliozin on bone microarchitecture in elderly patients with type 2 diabetes: Study protocol for a randomized controlled trial using second- generation high-resolution peripheral quantitative computed tomography (HR-pQCT) Ai Haraguchi Nagasaki Daigaku https://orcid.org/0000-0002-0671-2530 Riyoko Shigeno Nagasaki Daigaku Ichiro Horie ( [email protected] ) https://orcid.org/0000-0003-3430-5796 Shimpei Morimoto Nagasaki Daigaku Ayako Ito Nagasaki Daigaku Ko Chiba Nagasaki Daigaku Yurika Kawazoe Nagasaki Daigaku Shigeki Tashiro Nagasaki Daigaku Junya Miyamoto Nagasaki Daigaku Shuntaro Sato Nagasaki Daigaku Hiroshi Yamamoto Nagasaki Daigaku Makoto Osaki Nagasaki Daigaku Atsushi Kawakami Nagasaki Daigaku Norio Abiru Nagasaki Daigaku Page 1/18 Study protocol Keywords: type 2 diabetes, luseogliozin, SGLT2 inhibitor, HR-pQCT, fracture, bone Posted Date: September 6th, 2019 DOI: https://doi.org/10.21203/rs.2.14017/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published at Trials on May 5th, 2020. See the published version at https://doi.org/10.1186/s13063-020-04276-4. Page 2/18 Abstract Background Elderly patients with type 2 diabetes mellitus (T2DM) have an increased risk of bone fracture independent of their bone mineral density (BMD), which is explained mainly by the deteriorated bone quality in T2DM compared to non-diabetic adults. Sodium-glucose co-transporter (SGLT) 2 inhibitors have been studied in several trials in T2DM, and the Canagliozin Cardiovascular Assessment Study showed an increased fracture risk related to treatment with the SGLT2 inhibitor canagliozin, although no evidence of increased fracture risk with treatment with other SGLT2 inhibitors has been reported.
  • Comparison of Tofogliflozin 20 Mg and Ipragliflozin 50 Mg Used Together

    Comparison of Tofogliflozin 20 Mg and Ipragliflozin 50 Mg Used Together

    2017, 64 (10), 995-1005 Original Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study Soichi Takeishi, Hiroki Tsuboi and Shodo Takekoshi Department of Diabetes, General Inuyama Chuo Hospital, Inuyama 484-8511, Japan Abstract. To investigate whether sodium glucose co-transporter 2 inhibitors (SGLT2i), tofogliflozin or ipragliflozin, achieve optimal glycemic variability, when used together with insulin glargine 300 U/mL (Glargine 300). Thirty patients with type 2 diabetes were randomly allocated to 2 groups. For the first group: After admission, tofogliflozin 20 mg was administered; Fasting plasma glucose (FPG) levels were titrated using an algorithm and stabilized at 80 mg/dL level with Glargine 300 for 5 days; Next, glucose levels were continuously monitored for 2 days using continuous glucose monitoring (CGM); Tofogliflozin was then washed out over 5 days; Subsequently, ipragliflozin 50 mg was administered; FPG levels were titrated using the same algorithm and stabilized at 80 mg/dL level with Glargine 300 for 5 days; Next, glucose levels were continuously monitored for 2 days using CGM. For the second group, ipragliflozin was administered prior to tofogliflozin, and the same regimen was maintained. Glargine 300 and SGLT2i were administered at 8:00 AM. Data collected on the second day of measurement (mean amplitude of glycemic excursion [MAGE], average daily risk range [ADRR]; on all days of measurement) were analyzed. Area over the glucose curve (<70 mg/dL; 0:00 to 6:00, 24-h), M value, standard deviation, MAGE, ADRR, and mean glucose levels (24-h, 8:00 to 24:00) were significantly lower in patients on tofogliflozin than in those on ipragliflozin.
  • 202293Orig1s000

    202293Orig1s000

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 202293Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Office of Medication Error Prevention and Risk Management Final Risk Evaluation and Mitigation Strategy (REMS) Review Date: December 20, 2013 Reviewer(s): Amarilys Vega, M.D., M.P.H, Medical Officer Division of Risk Management (DRISK) Team Leader: Cynthia LaCivita, Pharm.D., Team Leader DRISK Drug Name(s): Dapagliflozin Therapeutic Class: Antihyperglycemic, SGLT2 Inhibitor Dosage and Route: 5 mg or 10 mg, oral tablet Application Type/Number: NDA 202293 Submission Number: Original, July 11, 2013; Sequence Number 0095 Applicant/sponsor: Bristol-Myers Squibb and AstraZeneca OSE RCM #: 2013-1639 and 2013-1637 *** This document contains proprietary and confidential information that should not be released to the public. *** Reference ID: 3426343 1 INTRODUCTION This review documents DRISK’s evaluation of the need for a risk evaluation and mitigation strategy (REMS) for dapagliflozin (NDA 202293). The proposed proprietary name is Forxiga. Bristol-Myers Squibb and AstraZeneca (BMS/AZ) are seeking approval for dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). Bristol-Myers Squibb and AstraZeneca did not submit a REMS or risk management plan (RMP) with this application. At the time this review was completed, FDA’s review of this application was still ongoing. 1.1 BACKGROUND Dapagliflozin. Dapagliflozin is a potent, selective, and reversible inhibitor of the human renal sodium glucose cotransporter 2 (SGLT2), the major transporter responsible for renal glucose reabsorption.
  • Populationsweite Utilisationsuntersuchung in Den Chronischen Krankheitsbildern Hypertonie, Hyperlipid¨Amieund Typ 2 Diabetes Mellitus –

    Populationsweite Utilisationsuntersuchung in Den Chronischen Krankheitsbildern Hypertonie, Hyperlipid¨Amieund Typ 2 Diabetes Mellitus –

    Ruhr-Universit¨atBochum Prof. Dr. rer. nat. Hans J. Trampisch Dienstort: Abteilung f¨urMedizinische Informatik, Biometrie und Epidemiologie Populationsweite Utilisationsuntersuchung in den chronischen Krankheitsbildern Hypertonie, Hyperlipid¨amieund Typ 2 Diabetes Mellitus { Eine Studie des Projekts PUKO-BHD an der Medizinischen Universit¨atWien Inaugural-Dissertation zur Erlangung des Doktorgrades der Medizin einer Hohen Medizinischen Fakult¨at der Ruhr-Universit¨atBochum vorgelegt von: Lisanne M. Jandeck aus Herford 2014 Dekan: Prof. Dr. med. Albrecht Bufe Referent: Prof. Dr. rer. nat. Hans J. Trampisch Korreferent: Prof. Dr. med. J¨urgenWindeler Tag der M¨undlichen Pr¨ufung:09.02.2017 Abstract Jandeck Lisanne M. Populationsweite Utilisationsuntersuchung in den chronischen Krankheitsbildern Hypertonie, Hyperlipid¨amieund Typ 2 Diabetes Mellitus Problem: Hypertonie (HT), Hyperlipid¨amie(HL) und Typ 2 Diabetes Mellitus (DM) stellen die h¨aufigstenchronischen Erkrankungen in Osterreich¨ dar, besonders bei Uber-50j¨ahrigen.Die¨ Zielsetzung dieser Teilstudie Utilisation\ des Projekts mit " dem Titel PUKO-BHD { Pr¨avalenz, Utilisation, Kosten und Outcome bei Blut- " hochdruck, Hyperlipid¨amieund Typ 2 Diabetes Mellitus\ ist eine populationsweite epidemiologische Untersuchung zu der Utilisation von Arzneimitteln zur Behand- lung dieser Krankheiten, insbesondere in Bezug auf Mehrfachverschreibungen (dou- ble prescriptions, DP) und Verschreibungen von Kombinationen von Wirkstoffen, die (schwerwiegende) Wechselwirkungen erzeugen k¨onnen (drug-drug
  • Clinical Comparison of Tofogliflozin and Empagliflozin Based on An

    Clinical Comparison of Tofogliflozin and Empagliflozin Based on An

    Obesity Medicine 14 (2019) 100088 Contents lists available at ScienceDirect Obesity Medicine journal homepage: www.elsevier.com/locate/obmed Original research Clinical comparison of tofogliflozin and empagliflozin based on an analysis of 24-h accumulated urine in Japanese patients with type 2 diabetes mellitus T ∗ Kazuo Kobayashia, , Masao Toyodab, Nobuo Hatoric a Kobayashi Clinic of Internal Medicine, Sagamihara, Japan b Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan c Kobayashi Hospital, Odawara, Japan ARTICLE INFO ABSTRACT Keywords: Aim: In Japan, six sodium-glucose co-transporter 2 inhibitors have been approved for use, and some agents are Tofogliflozin associated with a significant decrease in cardiovascular events. In this study, the effects of tofogliflozin and Empagliflozin empagliflozin were compared. 24-H accumulated urine Methods: Patients with type 2 diabetes mellitus who were administered tofogliflozin (n = 10) and empagliflozin Sodium-glucose co-transporter 2 inhibitor (n = 12) were extracted. The clinical parameters and 24-h accumulated urine samples before and after 48 weeks Hematocrit were analyzed with generalized linear mixed model. Results: Both groups showed significant differences in the following parameters: body weight (p < 0.0001), mean blood pressure (p = 0.006), glycated hemoglobinA1c (p < 0.0001), alanine aminotransferase (p < 0.0001), high-density lipoprotein cholesterol (p < 0.0001), homeostatic model assessment 2 (%S) (p = 0.006), volume of 24-h accumulated urine (p < 0.0001), and 24-h urine glucose excretion (p < 0.0001). The hematocrit differed significantly over the study period (p < 0.0001); however, empaglifozin had a sig- nificantly stronger effect on the hematocrit than tofoglifozin (p = 0.007).
  • Glomerular Hyperfiltration in Diabetes

    Glomerular Hyperfiltration in Diabetes

    BRIEF REVIEW www.jasn.org Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment Lennart Tonneijck,* Marcel H.A. Muskiet,* Mark M. Smits,* Erik J. van Bommel,* † ‡ Hiddo J.L. Heerspink, Daniël H. van Raalte,* and Jaap A. Joles *Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands; †Department of Clinical Pharmacology, University Medical Center Groningen, Groningen, The Netherlands; and ‡Department of Nephrology and Hypertension, University Medical Center, Utrecht, The Netherlands ABSTRACT An absolute, supraphysiologic elevation in GFR is observed early in the natural characterized by an absolute, supraphy- history in 10%–67% and 6%–73% of patients with type 1 and type 2 diabetes, siologic increase in whole-kidney GFR respectively. Moreover, at the single-nephron level, diabetes-related renal hemo- (i.e., the sum of filtration in all function- dynamic alterations—as an adaptation to reduction in functional nephron mass and/ ing nephrons) (Figure 1). This early or in response to prevailing metabolic and (neuro)hormonal stimuli—increase glo- clinical entity, known as glomerular hy- merular hydraulic pressure and transcapillary convective flux of ultrafiltrate and perfiltration, is the resultant of obesity macromolecules. This phenomenon, known as glomerular hyperfiltration, classically and diabetes-induced changes in struc- has been hypothesized to predispose to irreversible nephron damage, thereby con- tural and dynamic factors that deter- tributing to initiation and progression of kidney disease in diabetes. However, ded- mine GFR.5 Reported prevalences of icated studies with appropriate diagnostic measures and clinically relevant end hyperfiltration at the whole-kidney level points are warranted to confirm this assumption. In this review, we summarize the vary greatly: between 10% and 67% in hitherto proposed mechanisms involved in diabetic hyperfiltration, focusing on type 1 diabetes mellitus (T1DM) (with ultrastructural, vascular, and tubular factors.
  • Effect of Tofogliflozin on Arterial Stiffness in Patients with Type 2

    Effect of Tofogliflozin on Arterial Stiffness in Patients with Type 2

    Katakami et al. Cardiovasc Diabetol (2021) 20:4 https://doi.org/10.1186/s12933-020-01206-1 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Efect of tofoglifozin on arterial stifness in patients with type 2 diabetes: prespecifed sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial Naoto Katakami1,2* , Tomoya Mita3, Hidenori Yoshii4, Toshihiko Shiraiwa5, Tetsuyuki Yasuda6, Yosuke Okada7, Keiichi Torimoto7, Yutaka Umayahara8, Hideaki Kaneto9, Takeshi Osonoi10, Tsunehiko Yamamoto11, Nobuichi Kuribayashi12, Kazuhisa Maeda13, Hiroki Yokoyama14, Keisuke Kosugi15, Kentaro Ohtoshi16, Isao Hayashi17, Satoru Sumitani18, Mamiko Tsugawa19, Kayoko Ryomoto20, Hideki Taki21, Tadashi Nakamura22, Satoshi Kawashima23, Yasunori Sato24, Hirotaka Watada3, Iichiro Shimomura1 and On behalf of the UTOPIA study investigators Abstract Background: Tofoglifozin, an SGLT2 inhibitor, is associated with favorable metabolic efects, including improved glycemic control and serum lipid profle and decreased body weight, visceral adipose tissue, and blood pressure (BP). This study evaluated the efects of tofoglifozin on the brachial-ankle pulse wave velocity (baPWV) in patients with type 2 diabetes (T2DM) without a history of apparent cardiovascular disease. Methods: The using tofoglifozin for possible better intervention against atherosclerosis for type 2 diabetes patients (UTOPIA) trial is a prospective, randomized, open-label, multicenter, parallel-group, comparative study. As one of the prespecifed secondary outcomes,
  • Identification of SGLT2 Inhibitor Ertugliflozin As a Treatment

    Identification of SGLT2 Inhibitor Ertugliflozin As a Treatment

    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.18.448921; this version posted June 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Identification of SGLT2 inhibitor Ertugliflozin as a treatment for COVID-19 using computational and experimental paradigm Shalini SaxenaA, Kranti MeherC, Madhuri RotellaC, Subhramanyam VangalaC, Satish ChandranC, Nikhil MalhotraB, Ratnakar Palakodeti B, Sreedhara R Voleti A*, and Uday SaxenaC* A In Silico Discovery Research Academic Services (INDRAS) Pvt. Ltd. 44-347/6, Tirumalanagar, Moula Ali, Hyderabad – 500040, TS, India B Tech Mahindra Gateway Building, Apollo Bunder, Mumbai-400001, Maharashtra, India C Reagene Innovation Pvt. Ltd. 18B, ASPIRE-BioNEST, 3rd Floor, School of Life Sciences, University of Hyderabad, Gachibowli, Hyderabad – 500046, TS, India *Corresponding Authors email address: [email protected] [email protected] Abstract Drug repurposing can expedite the process of drug development by identifying known drugs which are effective against SARS-CoV-2. The RBD domain of SARS-CoV-2 Spike protein is a promising drug target due to its pivotal role in viral-host attachment. These specific structural domains can be targeted with small molecules or drug to disrupt the viral attachment to the host proteins. In this study, FDA approved Drugbank database were screened using a virtual screening approach and computational chemistry methods. Five drugs were short listed for further profiling based on docking score and binding energies. Further these selected drugs were tested for their in vitro biological activity.